Trial Profile
A Real World Study of Anlotinib for Patients With Advanced Medullary Thyroid Carcinoma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Carcinoma; Medullary thyroid cancer
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 28 Apr 2023 New trial record